Thomas Marron, MD, PhD, on the Next Steps in Phase 1 Trial Investigating PGV-001


Marron discussed the next steps to a trial of PGV-001, specifically centered around determining the immunogenicity of vaccinated patients against their antigens.

Thomas Marron, MD, PhD, of the Icahn School of Medicine at Mount Sinai, spoke with CancerNetwork® at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 about the next steps in a phase 1 trial of PGV-001, focusing on the immunogenicity of the cohort of vaccinated patients against their antigens.


Right now, we’re in the process of measuring the immunogenicity, basically the degree to which we successfully vaccinated these patients against their antigens. And we’re also looking at subsequent biopsies from patients who did have recurrent disease after the vaccine to see if there [are] any changes in the epitopes that are present or the antigens that are present in those recurrent tumors. In the poster, we show some data demonstrating that we did successfully prime a T-cell response, both the CD4 and the CD8 T-cell responses, against the neoantigens with which we vaccinated. And we’re hoping to see similar results as we continue our immune monitoring of the blood samples from the remaining patients.


Marron TU, Saxena M, Bhardwaj N, et al. An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001). Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract LB048.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content